Diagnostic testing for GERD has evolved to include multi esophageal sites (distal, proximal and hypopharyngeal monitoring), wireless pH, and oropharyngeal devices. The versatility of the devices has increased our ability to better understand the role of acid reflux in various disorders involving reflux of acid. Wireless pH monitoring improves patient comfort and allows monitoring for gastroesophageal reflux events over several days. Ambulatory MII-pH monitoring is another exciting diagnostic tool, which is capable of detecting more than one type of reflux and achieves higher sensitivity and specificity to detect GERD than endoscopy or pH-metry. It is useful in patients with either typical or atypical reflux symptoms who are refractory to proton pump inhibitor (PPI) therapy. In this setting, MII-pH can be performed on PPI therapy to assess the efficacy of PPIs and the role of nonacid or acid reflux in persistent symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.giec.2008.12.009 | DOI Listing |
BMC Surg
January 2025
Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Objective: Proximal gastrectomy (PG) is commonly used to remove proximal gastric cancer leading to gastroesophageal reflux and requires digestive tract reconstruction. This study is to compare the performance of esophagogastrostomy (EG), jejunal interposition (JI), and double tract reconstruction (DTR) on post-PG reconstruction effectiveness.
Methods: A retrospective study was conducted using the clinical data of 94 PG patients who underwent digestive tract reconstruction by EG (37 patients), JI (29 patients) or DTR (28 patients).
Kidney360
January 2025
Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Background: Epidemiological associations between kidney stone disease (KSD) and gastrointestinal disorders have been reported, and intestinal homeostasis plays a critical role in stone formation. However, the underlying intrinsic link is not adequately understood. This study aims to investigate the genetic associations between these two types of diseases.
View Article and Find Full Text PDFCureus
December 2024
College of Medicine, Al-Maarifa University, Riyadh, SAU.
Introduction The rise of vaping, especially among young adults in Saudi Arabia, has raised concerns due to the lack of awareness of the health risks associated with electronic cigarette use. This study examines the prevalence of gastroesophageal reflux disease (GERD) among university students in Riyadh, focusing on smoking behaviors and their influence on GERD symptoms. Methodology This cross-sectional study was conducted from July to September 2024, including random students aged 18 and above from several universities in Riyadh city.
View Article and Find Full Text PDFIntroduction: Potassium-competitive acid blockers are effective against proton pump inhibitor-refractory gastroesophageal reflux disease; however, their long-term use is associated with economic disadvantages. Endoscopic procedures may reduce potassium-competitive acid blocker use. This study aimed to determine the optimal treatment strategy for patients with proton pump inhibitor-refractory gastroesophageal reflux disease from a cost-effectiveness perspective.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Gastroenterology, CHA Ilsan Medical Center, Ilsan, Republic of Korea.
In patients with gastroesophageal reflux disease (GERD) whose symptoms improve with acid-suppression therapy, on-demand treatment could constitute maintenance therapy. This study investigated the comparative efficacy and safety of on-demand tegoprazan and proton-pump inhibitor (PPI) therapy in GERD. From six university hospitals in the Daejeon-Chungcheong region, we enrolled patients with GERD who had experienced symptomatic improvement with acid-suppressive therapy and, using a randomization table, randomly allocated these participants to two groups: to receive either tegoprazan 50 mg + esomeprazole placebo or tegoprazan placebo + esomeprazole 20 mg, respectively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!